



Canada House's Abba Medix Corp. announces the launch of www.abbamedixgenetics.com to support seed sales to Canadian LPs

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

TORONTO, Oct. 17, 2018 -- Canada House Wellness Group Inc ("Canada House" or the "Company") (CSE: CHV) is proud to announce that Abba Medix Corp, its wholly owned Licensed Producer (LP) which is licensed to sell cannabis seeds to other Canadian LPs, has today launched its website, <http://www.abbamedixgenetics.com>, an online e-commerce platform aimed at selling seeds to the Canadian LP community. The Canadian Cannabis sector suffers from a lack of readily available quality starting genetics and ancillary materials. Abba Medix Genetics provides a solution to this pressing challenge.

Through the Abba Medix Genetics portal, Licensed Producers can register for access to the Abba Medix Genetics website where they can directly purchase over 60 strains of seeds, ensuring that the genetics offer superior commercial production opportunities. Abba Medix Genetics intends to increase the number of strains held in their facility through their exclusive seed bank relationship in Europe. The seeds are sought-after phenotypes from top-quality breeders which have high germination rates and arrive at the LP Phyto sanitized and are already approved by Health Canada.

"We offer Abba Medix Genetics as a solution to some of the biggest challenges facing Canada's Licensed Producers in this new era of legalized cannabis," says Chris Churchill-Smith, CEO of Canada House. "Abba Medix Genetics' seeds will offer LPs efficient access to starting materials for cannabis crops, ensuring access to quality, non-contaminated starting materials approved by Health Canada," says Churchill-Smith, "LPs will commonly purchase clones from other LPs rather than seeds, which doesn't ensure the quality of harvests, and risks bringing contaminants into growing facilities," Churchill-Smith explained.

As legalization takes hold, there have been growing concerns about the supply of cannabis to meet the demand of the predicted 5 million cannabis consumers in Canada, along with the 330,758 patients who are currently registered under Canada's Access to Cannabis for Medical Purposes Regulation (ACMPR). At the same time, LPs face challenges when accessing quality starting materials, and this will address shortages in the supply chain for seeds.

Access to Abba Medix Genetics is offered strictly to Canada's Licensed Producers and can be found at <http://www.abbamedixgenetics.com>. LPs can build a shopping cart and receive a quote for products before completing a sale.

For further information, please contact:

Boom Capital Markets
Steve Low
647-620-5101
steve@boomcapitalmarkets.com

Canada House Wellness Group Inc.
Chris Churchill-Smith, CEO
514-313-0102
chris.smith@canadahouse.ca

Cautionary Statement Regarding Forward Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company's clinic, production and technology businesses, its future plans, the Company's markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as "may", "will", "could", "should", "would", "likely", "possible", "expect", "intend", "estimate", "anticipate", "believe", "plan", "objective" and "continue" (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied

in making forward-looking statements may be found in the Company's most recent annual and interim Management's Discussion and Analysis under "Risk and Uncertainties" as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.